In this episode, we are sharing a panel on “Nutrition at the Forefront of Health” from the S2G summit. Matt Walker, Managing Director on S2G’s Food & Agriculture team, interviewed Susan Bukata, Professor and Chair of Orthopedic Surgery at the University of California San Diego, Bill Dietz, Director of Research and Policy at the Global Food Institute at George Washington University, and Howard Lossing, former CEO of Cambrooke Therapeutics, about the growing influence and importance of nutrition in the healthcare sector. The panelists discussed the need for more science and data-backed nutrition interventions while also emphasizing the key role that education across stakeholder groups will play in realizing widespread adoption. They draw from their remarkable and lengthy careers in the healthcare sector to provide both optimism and realism to the increasingly popular field of food and nutrition-based health solutions.
Key Topics:
Resources:
This content is for informational purposes only, should not be taken as legal, business, tax or investment advice, or be used to evaluate any investment or security, and is not directed at any investor or potential investor in any investment vehicle sponsored by S2G. Investing involves risk, including the risk of loss. Specific companies mentioned in this podcast are for educational purposes and should not be construed as an endorsement of any kind. S2G holds positions in the companies referenced, but this podcast is for information purposes only and is not intended to promote any such company. All views of the guests on this podcast are solely their opinions and do not reflect the opinions of S2G. Any past performance discussed is not indicative of future results. Chuck Templeton is a Managing Partner at S2G Investments. All Chuck's views, and the views of the guests on this podcast, are solely their opinions and do not necessarily reflect the opinions of S2G. The views expressed herein are opinions based on certain assumptions and subject to change.
For more important information, please see s2ginvestments.com/disclosures.